announced today that the U.S. Food and Medication Administration’s Cardiovascular and Renal Drugs Advisory Committee recommended authorization of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in sufferers with non-valvular atrial fibrillation . The committee voted 9-2 and only rivaroxaban in sufferers with AF who are at threat of stroke and systemic embolism. We are pleased with the committee’s suggestion and look forward to working with the FDA to help make this important therapy available in the U.S., stated Peter M.We hope this document will lay the foundation for improving usage of treatment and help us close, or at least narrow, the gender gap in reproductive wellness. The experts remember that improving men's sexual health may also help sustain latest gains in women's reproductive health. During the last decade, women's usage of reproductive and sexual wellness services offers improved by leaps and bounds. This is a laudable achievement, but only half the battle, says report co-author Anne Rompalo, M.D., Sc.M., an infectious disease expert and epidemiologist at Johns Hopkins Bayview INFIRMARY.